Microbiota in Cancer Immunotherapy: The Next Milestone of Immuno-oncology?

Ting, Nick Lung-Ngai; Yu, Jun

doi:10.1007/978-981-19-4492-5_17

Cited by 2 publications

(1 citation statement)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Groundbreaking work in clinical studies has confirmed that the gut microbiome composition may impact the effectiveness of immune checkpoint therapy in a number of tumor types, including sites quite distant from the gastrointestinal tract [ 133 ]. Prospective studies are currently being conducted to explore dietary modulation, probiotics, antibiotics, and fecal microbiota transplantation as potential methods for manipulating the gut microbiome and promoting a more favorable immune response [ 134 ]. FMT, specifically, could be leveraged to enhance the systemic and antitumor immune response in cancer patients receiving ICIs [ 135 , 136 , 137 , 138 , 139 ].…”

Section: Connection Between Microbiota the Immune System Response Of ...mentioning

confidence: 99%

The Influence of the Microbiome on Immunotherapy for Gastroesophageal Cancer

Dadgar,

Edlukudige Keshava,

Raj

et al. 2023

Cancers

View full text Add to dashboard Cite

Immunotherapy has shown promise as a treatment option for gastroesophageal cancer, but its effectiveness is limited in many patients due to the immunosuppressive tumor microenvironment (TME) commonly found in gastrointestinal tumors. This paper explores the impact of the microbiome on the TME and immunotherapy outcomes in gastroesophageal cancer. The microbiome, comprising microorganisms within the gastrointestinal tract, as well as within malignant tissue, plays a crucial role in modulating immune responses and tumor development. Dysbiosis and reduced microbial diversity are associated with poor response rates and treatment resistance, while specific microbial profiles correlate with improved outcomes. Understanding the complex interactions between the microbiome, tumor biology, and immunotherapy is crucial for developing targeted interventions. Microbiome-based biomarkers may enable personalized treatment approaches and prediction of patient response. Interventions targeting the microbiome, such as microbiota-based therapeutics and dietary modifications, offer the potential for reshaping the gut microbiota and creating a favorable TME that enhances immunotherapy efficacy. Further research is needed to reveal the underlying mechanisms, and large-scale clinical trials will be required to validate the efficacy of microbiome-targeted interventions.

show abstract